225 related articles for article (PubMed ID: 8540706)
1. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
3. Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor.
McMahon JB; Buckheit RW; Gulakowski RJ; Currens MJ; Vistica DT; Shoemaker RH; Stinson SF; Russell JD; Bader JP; Narayanan VL; Schultz RJ; Brouwer WG; Felauer EE; Boyd MR
J Pharmacol Exp Ther; 1996 Jan; 276(1):298-305. PubMed ID: 8558446
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents.
Hara H; Fujihashi T; Sakata T; Kaji A; Kaji H
AIDS Res Hum Retroviruses; 1997 May; 13(8):695-705. PubMed ID: 9168238
[TBL] [Abstract][Full Text] [Related]
5. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
[TBL] [Abstract][Full Text] [Related]
6. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
Chong KT; Pagano PJ; Hinshaw RR
Antimicrob Agents Chemother; 1994 Feb; 38(2):288-93. PubMed ID: 7514857
[TBL] [Abstract][Full Text] [Related]
7. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.
Buckheit RW; White EL; Fliakas-Boltz V; Russell J; Stup TL; Kinjerski TL; Osterling MC; Weigand A; Bader JP
Antimicrob Agents Chemother; 1999 Aug; 43(8):1827-34. PubMed ID: 10428899
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.
Buckheit RW; Kinjerski TL; Fliakas-Boltz V; Russell JD; Stup TL; Pallansch LA; Brouwer WG; Dao DC; Harrison WA; Schultz RJ
Antimicrob Agents Chemother; 1995 Dec; 39(12):2718-27. PubMed ID: 8593008
[TBL] [Abstract][Full Text] [Related]
9. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
10. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine.
Hooker DJ; Tachedjian G; Solomon AE; Gurusinghe AD; Land S; Birch C; Anderson JL; Roy BM; Arnold E; Deacon NJ
J Virol; 1996 Nov; 70(11):8010-8. PubMed ID: 8892925
[TBL] [Abstract][Full Text] [Related]
11. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine.
Kong XB; Zhu QY; Ruprecht RM; Watanabe KA; Zeidler JM; Gold JW; Polsky B; Armstrong D; Chou TC
Antimicrob Agents Chemother; 1991 Oct; 35(10):2003-11. PubMed ID: 1722077
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
13. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
15. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
16. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.
Borkow G; Arion D; Wainberg MA; Parniak MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):259-63. PubMed ID: 9925515
[TBL] [Abstract][Full Text] [Related]
17. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.
Young SD; Britcher SF; Tran LO; Payne LS; Lumma WC; Lyle TA; Huff JR; Anderson PS; Olsen DB; Carroll SS
Antimicrob Agents Chemother; 1995 Dec; 39(12):2602-5. PubMed ID: 8592986
[TBL] [Abstract][Full Text] [Related]
18. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
[TBL] [Abstract][Full Text] [Related]
19. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.
Canard B; Sarfati SR; Richardson CC
J Biol Chem; 1998 Jun; 273(23):14596-604. PubMed ID: 9603976
[TBL] [Abstract][Full Text] [Related]
20. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]